abstract |
A feature of the invention is the combination of doxorubicin or Doxil with a checkpoint inhibitor (eg, an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a GITR ligand, or an OX40 fusion protein (FP)) And methods of using the combination to enhance the anti-tumor activity of an individual. |